Median Technologies Crecimiento futuro

Future controles de criterios 1/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Median Technologies de 9.1% y 21.8% respectivamente, mientras que el BPA crecerá en un 14% al año.

Información clave

6.2%

Tasa de crecimiento de los beneficios

11.0%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Healthcare Services	28.1%
Tasa de crecimiento de los ingresos	17.9%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	19 Jun 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

DB:4ZG - Estimaciones futuras de los analistas y datos financieros pasados (EUR Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	39	-19	-20	-17	3
12/31/2025	30	-22	-21	-20	4
12/31/2024	24	-24	-22	-22	3
12/31/2023	23	-23	-22	-20	N/A
9/30/2023	23	-22	-20	-19	N/A
6/30/2023	23	-21	-19	-18	N/A
3/31/2023	23	-21	-18	-17	N/A
12/31/2022	24	-20	-17	-16	N/A
9/30/2022	24	-19	-16	-15	N/A
6/30/2022	23	-19	-15	-14	N/A
3/31/2022	22	-19	-13	-12	N/A
12/31/2021	21	-19	-11	-10	N/A
9/30/2021	19	-18	-10	-10	N/A
6/30/2021	18	-18	-10	-9	N/A
3/31/2021	16	-15	-8	-7	N/A
12/31/2020	14	-13	-6	-5	N/A
9/30/2020	12	-11	-4	-4	N/A
6/30/2020	11	-8	-3	-2	N/A
3/31/2020	10	-8	-4	-3	N/A
12/31/2019	9	-8	-5	-4	N/A
9/30/2019	8	-9	-8	-7	N/A
6/30/2019	7	-11	-11	-10	N/A
3/31/2019	7	-13	-13	-13	N/A
12/31/2018	6	-15	-16	-16	N/A
9/30/2018	7	-16	-17	-17	N/A
6/30/2018	7	-17	-18	-18	N/A
3/31/2018	7	-17	-16	-16	N/A
12/31/2017	8	-17	-14	-14	N/A
9/30/2017	8	-16	N/A	-12	N/A
6/30/2017	7	-14	N/A	-10	N/A
3/31/2017	7	-12	N/A	-9	N/A
12/31/2016	6	-9	N/A	-8	N/A
9/30/2016	6	-8	N/A	-6	N/A
6/30/2016	5	-7	N/A	-5	N/A
3/31/2016	5	-6	N/A	-4	N/A
12/31/2015	4	-6	N/A	-4	N/A
9/30/2015	3	-5	N/A	-4	N/A
6/30/2015	2	-5	N/A	-5	N/A
3/31/2015	2	-5	N/A	-4	N/A
12/31/2014	2	-4	N/A	-3	N/A
9/30/2014	1	-4	N/A	N/A	N/A
6/30/2014	1	-4	N/A	N/A	N/A
3/31/2014	1	-4	N/A	N/A	N/A
12/31/2013	1	-4	N/A	-4	N/A
9/30/2013	1	-4	N/A	N/A	N/A
6/30/2013	1	-4	N/A	N/A	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que 4ZG siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que 4ZG siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que 4ZG siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (21.8% al año) de 4ZG crezcan más rápidamente que los del mercado German (5.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 17.9% al año) de 4ZG crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de 4ZG se prevé que sea elevada dentro de 3 años.

Median Technologies Crecimiento futuro

Future controles de criterios 1/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Forecast to breakeven in 2025

Recent updates

New major risk - Financial position

Median Technologies SA, Annual General Meeting, Jun 19, 2024

Full year 2023 earnings released: €1.25 loss per share (vs €1.28 loss in FY 2022)

New major risk - Share price stability

New minor risk - Share price stability

Median Technologies SA to Report Fiscal Year 2023 Results on Apr 25, 2024

Median Technologies's iBiopsy HCC Detection AI Model Developed on the PHELICAR Clinical Data Registry, to Be Presented at the ESMO Congress

Median Technologies Appoints Ben Mcdonald to Its Board of Directors

Median Technologies SA, Annual General Meeting, Oct 10, 2023

Median Technologies SA to Report First Half, 2023 Results on Oct 19, 2023

Median Technologies SA announced that it expects to receive €10 million in funding from Lake Bridge Capital Inc

Median Technologies SA announced that it expects to receive €10 million in funding from Lake Bridge Capital Inc

New major risk - Financial position

Median Technologies SA, Annual General Meeting, Jun 20, 2023

Full year 2022 earnings released: €1.28 loss per share (vs €1.25 loss in FY 2021)

Forecast to breakeven in 2025

Median Technologies SA to Report Fiscal Year 2022 Results on Apr 20, 2023

No independent directors

First half 2022 earnings released: €0.57 loss per share (vs €0.65 loss in 1H 2021)

Median Technologies Announces Formation of Clinical Advisory Board for Ibiopsy Lung Cancer Screening

Median Technologies SA to Report Q3, 2022 Results on Oct 20, 2022

Median Technologies SA Launches Imaging Lab, Spearheading the Integration of iBiopsy® Artificial Intelligence Technologies Into iCRO Imaging Services for Oncology Trials

Median Technologies SA, Annual General Meeting, Jun 14, 2022

No independent directors

Full year 2021 earnings released: €1.25 loss per share (vs €1.06 loss in FY 2020)

Median Technologies SA Files FDA 513(g) Regulatory Submission for iBiopsy® Lung Cancer Screening CADe/CADx Software as Medical Device

Median Technologies Announces New Outstanding Performance for Its iBiopsy® Lung Cancer Screening CADx With a Focus on Stage 1 Lung Cancer Characterization

First half 2021 earnings released: €0.65 loss per share (vs €0.39 loss in 1H 2020)

Median Technologies SA announced that it has received €28.1 million in funding

Full year 2020 earnings released: €1.05 loss per share (vs €0.66 loss in FY 2019)

Median Technologies Appoints Thomas Bonnefont as Chief Operating and Commercial Officer

Median Technologies Sa Unveils New iBiopsy® Clinical Development Plan on Lung Cancer Screening

Median Technologies Inks Major Research Collaboration Agreement With the University of California San Diego

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento